Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
